ProEncia Biotechnology Secures Pre-Seed Funding to Advance Novel Periodontal Disease Treatment Pipeline
Key Insights
ProEncia Biotechnology (search) has closed significant pre-seed funding to accelerate development of its next-generation periodontal disease (search) treatment pipeline targeting over one billion people globally affected by the condition.
The Twin Cities-based biopharma startup received patent confirmation from the USPTO for its novel compositions and methods for periodontal care, with the provisional patent now incorporated into a non-provisional PCT International application.
The company is developing multiple prophylactic and therapeutic products based on patent-pending technology, focusing on easy-to-use, non-toxic, and non-invasive oral care solutions for patients across all stages of periodontal disease (search) severity.
ProEncia Biotechnology (search), a Twin Cities-based biopharma startup, has closed significant pre-seed funding to accelerate development of its next-generation periodontal disease (search) treatment pipeline. The funding will support the development, commercialization, and licensing of novel, non-invasive periodontal care products designed for patients across all stages of periodontal disease severity.
The company is addressing a substantial global health challenge, with periodontal disease (search) affecting more than one billion people worldwide and over 100 million people in the United States, according to World Health Organization data cited by the company.
Patent Protection Secured
ProEncia announced that the United States Patent and Trademark Office (search) has confirmed its provisional patent application titled "Compositions and Method for Prophylactic, Symptomatic, Therapeutic, and Cosmetic Periodontal Care" has been incorporated into a non-provisional PCT International application and entered into the federal patent filing system. The provisional patent application number is 63/765,225, while the non-provisional PCT International application number is 19/548,447.
Treatment Innovation Focus
The company is developing multiple prophylactic and therapeutic products based on its patent-pending periodontal treatment technology. ProEncia's approach focuses on creating easy-to-use, non-toxic oral care solutions targeting conditions including gingivitis (search) and periodontitis (search).
"According to the World Health Organization, more than one billion people globally, and more than 100 million people in the U.S., suffer from periodontal disease (search)," said Tapos Ghosh, CEO and Co-Founder of ProEncia Biotechnology (search). "There's an urgent need for innovation to resolve this epidemic and bring safe, effective solutions to lifelong sufferers of this condition."
Market Opportunity and Clinical Impact
Austin Loeb, COO and Co-Founder of ProEncia Biotechnology (search), emphasized the commercial potential of the company's approach. "The commercial demand for a new approach to periodontal treatment is enormous," Loeb stated. "The ProEncia team is committed to advancing its groundbreaking treatment and expanding care options for periodontal disease (search) patients."
Company Background
Founded in 2022, ProEncia Biotechnology (search) was co-founded with scientific and clinical leadership from Dr. Tarun Ghosh and Dr. Thomas Hoover. The Minnesota-based company specializes in developing innovative periodontal care solutions for adult patients at all stages of periodontal disease (search).
Periodontal disease (search) encompasses conditions involving chronic and progressive inflammation, infection, and damage of tissues surrounding and supporting teeth, including gums, ligaments, and bone. The condition can lead to bleeding, sensitivity, halitosis, tooth mobility, tissue loss, bone loss, and other oral symptoms. Emerging research suggests potential links between periodontal disease and serious health conditions including Alzheimer's (search), dementia (search), heart disease (search), lung disease (search), worse COVID outcomes, and immune system compromise.